{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-21-003512","form_type":"8-K/A","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.942967+00:00","generated_at":"2026-06-28T09:09:55.856623+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Chemomab appoints Donald Marvin as CFO & COO, replacing Sigal Fattal effective Nov 8, 2021","bullets":["Sigal Fattal's engagement as interim CFO concluded by mutual agreement; she remains as senior consultant.","Donald Marvin named CFO, EVP & COO; base salary $460K, annual bonus target 45% of base.","Marvin receives 1.5% equity (4-yr vest) + up to 0.5% for strategic goals, $25K signing bonus.","Severance package of 12 months, increasing by 1 month every 2 years (max 18 months).","Marvin brings 35+ years experience; no family relationships or reportable transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-21-003512","json":"https://secwatch.observer/filing/0001178913-21-003512.json","markdown":"https://secwatch.observer/filing/0001178913-21-003512.md","text":"https://secwatch.observer/filing/0001178913-21-003512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003512/0001178913-21-003512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003512/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:09:55.856623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"351b5fca84","claim":"Donald Marvin was appointed as Chief Financial Officer, Executive Vice President and Chief Operating Officer at Chemomab Therapeutics Ltd..","evidence_excerpt":"it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003512/0001178913-21-003512-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer, Executive Vice President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}